[{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"84b9efcf-36bd-4449-8f61-5a867dd8b5f1","acronym":"NCI-2020-04163","url":"https://clinicaltrials.gov/study/NCT04435691","created_at":"2021-01-18T21:21:23.231Z","updated_at":"2025-02-25T16:37:56.003Z","phase":"Phase 1/2","brief_title":"Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia","source_id_and_acronym":"NCT04435691 - NCI-2020-04163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-06"},{"id":"61e57503-680e-4667-ac9e-45a1209fdaaf","acronym":"TT4B","url":"https://clinicaltrials.gov/study/NCT00734877","created_at":"2021-01-18T02:46:06.475Z","updated_at":"2025-02-25T14:55:10.781Z","phase":"Phase 3","brief_title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","source_id_and_acronym":"NCT00734877 - TT4B","lead_sponsor":"University of Arkansas","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-07-03"},{"id":"3925047f-59bc-4ff7-ae17-5986348b616c","acronym":"DEC10-VEN","url":"https://clinicaltrials.gov/study/NCT03404193","created_at":"2021-01-17T17:18:31.504Z","updated_at":"2024-07-02T16:35:24.415Z","phase":"Phase 2","brief_title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03404193 - DEC10-VEN","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 235","initiation":"Initiation: 01/18/2018","start_date":" 01/18/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-05"},{"id":"0c45dd0e-f439-463b-8d1f-a9be494b9943","acronym":"","url":"https://clinicaltrials.gov/study/NCT02808650","created_at":"2021-01-18T13:46:35.607Z","updated_at":"2024-07-02T16:35:25.681Z","phase":"Phase 1","brief_title":"Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02808650","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":" | ","alterations":" TP53 mutation • TP53 deletion • TP53 expression","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2017","start_date":" 02/27/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2023-12-20"},{"id":"a7b10d24-6834-4ab0-b432-bed5ee7f3e42","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062641","created_at":"2023-10-02T20:12:32.544Z","updated_at":"2024-07-02T16:35:30.152Z","phase":"Phase 2","brief_title":"Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL","source_id_and_acronym":"NCT06062641","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xpovio (selinexor) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-11-07"},{"id":"31d52b20-d299-4b75-8193-e28c00ee4069","acronym":"CLL2-GiVe","url":"https://clinicaltrials.gov/study/NCT02758665","created_at":"2021-01-18T13:31:39.869Z","updated_at":"2024-07-02T16:35:57.574Z","phase":"Phase 2","brief_title":"Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL","source_id_and_acronym":"NCT02758665 - CLL2-GiVe","lead_sponsor":"University of Ulm","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 deletion","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2023-01-16"},{"id":"f69db2be-05a6-45ef-a79d-7dae6afc1775","acronym":"","url":"https://clinicaltrials.gov/study/NCT01760655","created_at":"2021-01-18T07:44:19.143Z","updated_at":"2024-07-02T16:35:58.053Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT01760655","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 deletion • Chr del(5q) • Chr del(7q)","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/24/2012","start_date":" 12/24/2012","primary_txt":" Primary completion: 04/15/2022","primary_completion_date":" 04/15/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-01-06"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"a85171ef-412e-4d84-8d91-1401da7b26cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01809847","created_at":"2021-02-09T10:53:08.484Z","updated_at":"2024-07-02T16:37:29.027Z","phase":"Phase 2","brief_title":"Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation","source_id_and_acronym":"NCT01809847","lead_sponsor":"Technische Universität Dresden","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2016-09-19"}]